Last reviewed · How we verify
NCT04079595
Closed vs. Open Face Masks for Cranial Radiotherapy
NA trial testing Head immobilization mask in Brain Tumor in 60 participants. Completed in 31 May 2022.
28 February 2022
Quick facts
| Lead sponsor | University of Zurich |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | other |
| Enrollment | 60 |
| Start date | 9 December 2019 |
| Primary completion | 28 February 2022 |
| Estimated completion | 31 May 2022 |
| Sites | 1 location across Switzerland |
Drugs / interventions tested
- Head immobilization mask
Conditions studied
- Brain Tumor — all drugs for Brain Tumor →
- Brain Metastases — all drugs for Brain Metastases →
- Small Cell Lung Cancer — all drugs for Small Cell Lung Cancer →
- Meningioma — all drugs for Meningioma →
Sponsor
University of Zurich
Who can join
18 and older, any sex, with Brain Tumor or Brain Metastases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of the study is to evaluate whether open-face masks improve patient comfort/preference whilst maintaining immobilization performance as known for closed masks in patients undergoing whole or partial cranial radiotherapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04079595
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Brain Tumor
Currently open trials in the same condition.
- NCT07224503 — C-SMART vs BE Well for Patients With Brain Tumors · NA · recruiting
- NCT07323966 — Feasibility of Mask-Free Radiotherapy for Brain Tumor Patients · NA · recruiting
- NCT07122752 — Feasibility and Outcomes of 3D-printed External Cranial Orthosis After Craniectomy · active not recruiting
- NCT07105358 — Visual Plasticity Following Brain Lesions · NA · recruiting
- NCT06810544 — Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss · Phase 1, PHASE2 · recruiting
Other University of Zurich trials
Trials by the same sponsor.
- NCT07485699 — Soy Processing and Food Allergy · NA · not yet recruiting
- NCT07516912 — Evaluation of Free STI Testing Pilot Projects in Lucerne and Zurich, Switzerland · not yet recruiting
- NCT07473115 — Individualized Analgesia in the Intensive Care Unit With a New Pain Assessment Bundle and Protocolized Analgesia Adjustm · not yet recruiting
- NCT07524023 — Emotional-distress-based Integrated Care Programme in Patients With Stable COPD · NA · recruiting
- NCT06481982 — Value of Advanced MRI Techniques in the Assessment of Endometriosis · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04079595 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Zurich
- Last refreshed: 23 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04079595.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing